Columbia Trust Co 01012016 Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Columbia Trust Co 01012016 boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 11,191 shares of the company’s stock after purchasing an additional 311 shares during the quarter. Johnson & Johnson makes up approximately 1.0% of Columbia Trust Co 01012016’s portfolio, making the stock its 24th biggest holding. Columbia Trust Co 01012016’s holdings in Johnson & Johnson were worth $1,808,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. OLD Mission Capital LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $362,000. Ironwood Wealth Management LLC. grew its position in shares of Johnson & Johnson by 37.3% in the 1st quarter. Ironwood Wealth Management LLC. now owns 10,161 shares of the company’s stock worth $1,670,000 after acquiring an additional 2,761 shares in the last quarter. Hoylecohen LLC grew its position in shares of Johnson & Johnson by 31.3% in the 1st quarter. Hoylecohen LLC now owns 126,382 shares of the company’s stock worth $20,771,000 after acquiring an additional 30,109 shares in the last quarter. MBL Wealth LLC grew its position in shares of Johnson & Johnson by 23.9% in the 1st quarter. MBL Wealth LLC now owns 5,929 shares of the company’s stock worth $974,000 after acquiring an additional 1,144 shares in the last quarter. Finally, Fragasso Group Inc. grew its position in shares of Johnson & Johnson by 0.9% in the 1st quarter. Fragasso Group Inc. now owns 12,893 shares of the company’s stock worth $2,119,000 after acquiring an additional 120 shares in the last quarter. Institutional investors own 67.14% of the company’s stock.

Shares of JNJ stock opened at $160.24 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.11 and a current ratio of 1.34. Johnson & Johnson has a 1 year low of $142.86 and a 1 year high of $179.92. The stock has a fifty day moving average of $162.64 and a two-hundred day moving average of $167.35. The firm has a market capitalization of $421.85 billion, a PE ratio of 23.95, a price-to-earnings-growth ratio of 2.38 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Monday, October 18th. The company reported $2.60 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.35 by $0.25. Johnson & Johnson had a return on equity of 37.90% and a net margin of 19.55%. The company had revenue of $23.34 billion during the quarter, compared to analyst estimates of $23.72 billion. During the same quarter in the previous year, the firm posted $2.20 EPS. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 9.78 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 7th. Stockholders of record on Tuesday, November 23rd will be paid a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.65%. The ex-dividend date of this dividend is Monday, November 22nd. Johnson & Johnson’s dividend payout ratio is presently 63.38%.

JNJ has been the subject of several research reports. SVB Leerink reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, July 29th. Raymond James reduced their price objective on Johnson & Johnson from $183.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, October 20th. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $172.00 price objective for the company in a research report on Friday, October 22nd. Wells Fargo & Company restated a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, October 7th. Finally, Morgan Stanley lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective for the company. in a research report on Tuesday, September 7th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $187.78.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Article: What is the Book Value of a Share?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.